Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23,13:30-15:50
Computing Power × Human Endeavor × R&D Capability: New Paradigm of Innovative Drug R&D in the AI Era
Stay tuned
Conference Planning
Hongming Liang, Co-founder & CSO, Foxu.AI
13:30-13:40 AI medical technology is moving from a tech concept to clinical use
Qingsong Qin:Director of the Transfer, Translation, and Investment Department at Shanghai Clinical Innovation and Translational Research Institute
13:40-14:10 Computing Power × Human Ingenuity – The Re-Evolution of Innovative Drug R&D Organizations in the AI Era
Jianfeng Peng:Professor of Renmin University of China; Chairman, China Stone
14:10-14:35 In Silico Workforce in Highly Regulated R&D Scenarios: From Report Generation to Process Quality Control
Hongming Liang:Co-founder & CSO, Foxu.AI
14:35-14:50 Quantum-Enhanced In Silico: Simulating Clinical Trials Before First-in-Human
Yin Ma:Founder &COO, QBoson
14:50-15:30 How will AI transform the relationship between pharmaceutical companies and CRO/CMO over the next three years?
Alice Wang(Host):Director, CCB International Capital Limited
Tong Guo, Clinical Research Center CEO, Gao Bo Medical Group
Bingshi Guo, General Manager of Macromolecule R&D Platform, Jeyou Pharma
Lin Xia, Deputy General Manager of Dingtai Group and CMO of Dingtai Nanjing, former senior evaluator at CDE
15:30-15:50 Break